{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:57:54Z","timestamp":1791860274388,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ccell.2026.08.012","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:11:25Z","timestamp":1789571485000},"page":"2100-2107.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chemotherapy-free phase 1\/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"Si","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6697-7143","authenticated-orcid":false,"given":"Xianjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.08.012_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ccell.2026.08.012_bib2","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.ccell.2026.08.012_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","volume":"395","author":"O'Reilly","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.08.012_bib4","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.08.012_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1101\/gad.351863.124","article-title":"Genetics and biology of pancreatic ductal adenocarcinoma","volume":"39","author":"Ying","year":"2025","journal-title":"Genes Dev."},{"key":"10.1016\/j.ccell.2026.08.012_bib6","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ccell.2026.08.012_bib7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2026.01.001","article-title":"Emerging landscape of KRAS inhibitors in cancer treatment","volume":"44","author":"Riedl","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.08.012_bib8","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRAS(G12C) Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.08.012_bib9","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.08.012_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ccell.2026.08.012_bib11","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ccell.2026.08.012_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102525","article-title":"KRAS mutations promote PD-L1-mediated immune escape by ETV4 in lung adenocarcinoma","volume":"61","author":"Jia","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ccell.2026.08.012_bib13","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2025.43.16_suppl.8500","article-title":"First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced\/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study","volume":"43","author":"J\u00e4nne","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.08.012_bib14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.08.012_bib15","doi-asserted-by":"crossref","first-page":"S558","DOI":"10.1016\/j.annonc.2025.08.1484","article-title":"915O KRAS G12D inhibitor HRS-4642 in patients with KRAS G12D-mutant advanced solid tumors: A phase I trial","volume":"36","author":"Xiong","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.08.012_bib16","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.08.012_bib17","doi-asserted-by":"crossref","first-page":"S1626","DOI":"10.1016\/j.annonc.2025.09.099","article-title":"LBA84 Efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC)","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.08.012_bib18","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","article-title":"Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer","volume":"394","author":"Park","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.08.012_bib19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.2026.44.2_suppl.710","article-title":"Updated results of the phase 1\/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors","volume":"44","author":"Li","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.08.012_bib20","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2026.44.2_suppl.729","article-title":"A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of RNK08954 in patients with advanced solid tumors with a KRAS G12D mutation","volume":"44","author":"El-Hariry","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.08.012_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-026-04538-9","article-title":"KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRAS(G12D)-mutant pancreatic cancer: a phase 1b\/2 trial","author":"Cui","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.08.012_bib22","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2026.44.2_suppl.654","article-title":"Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced\/metastatic pancreatic duct adenocarcinoma (PDAC)","volume":"44","author":"Wainberg","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.08.012_bib23","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.annonc.2026.05.381","article-title":"Safety and efficacy of zoldonrasib (RMC-9805) plus chemotherapy in patients (pts) with 1L RAS G12D metastatic pancreatic adenocarcinoma (MPDAC)","volume":"37","author":"Wolpin","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.08.012_bib24","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.2026.44.2_suppl.704","article-title":"Efficacy and safety of ASP3082 monotherapy or in combination with mFOLFIRINOX in patients (pts) with pancreatic ductal adenocarcinoma (PDAC)","volume":"44","author":"Kasi","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.08.012_bib25","doi-asserted-by":"crossref","first-page":"PR012","DOI":"10.1158\/2326-6074.IO2025-PR012","article-title":"Abstract PR012: The RAS(ON) G12D-selective inhibitor RMC-9805 synergizes with anti-PD-1 to extend durability of antitumor activity in KRAS G12D-driven preclinical cancer models","volume":"13","author":"Menard","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2026.08.012_bib26","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.08.012_bib27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.08.012_bib28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/2159-8290.CD-25-1346","article-title":"Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor","volume":"16","author":"Xie","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.08.012_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2026.08.012_bib30","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1158\/1078-0432.CCR-21-1789","article-title":"Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513","volume":"27","author":"Chiorean","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.08.012_bib31","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.20.02232","article-title":"Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)","volume":"39","author":"Hecht","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.08.012_bib32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: A Review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ccell.2026.08.012_bib33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/1538-7445.AM2023-526","article-title":"Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers","volume":"83","author":"Jiang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.08.012_bib34","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1200\/JCO.2025.43.4_suppl.722","article-title":"Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)","volume":"43","author":"Garrido-Laguna","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.08.012_bib35","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.ccell.2024.06.005","article-title":"HRS-4642: The next piece of the puzzle to keep KRAS in check","volume":"42","author":"Flores-G\u00f3mez","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.08.012_bib36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2025.11.011","article-title":"Circulating tumor DNA as a biomarker in early phase clinical trials","volume":"44","author":"Tan","year":"2026","journal-title":"Cancer Cell"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826003892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826003892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:18:39Z","timestamp":1791818319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826003892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1535610826003892"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.08.012","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy-free phase 1\/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}